Literature DB >> 31455892

An analysis of genetic heterogeneity in untreated cancers.

Johannes G Reiter1, Marina Baretti2, Jeffrey M Gerold3, Alvin P Makohon-Moore4, Adil Daud5, Christine A Iacobuzio-Donahue4,6, Nilofer S Azad2, Kenneth W Kinzler2,7,8, Martin A Nowak9,10,11, Bert Vogelstein12,13,14,15.   

Abstract

Genetic intratumoural heterogeneity is a natural consequence of imperfect DNA replication. Any two randomly selected cells, whether normal or cancerous, are therefore genetically different. Here, we review the different forms of genetic heterogeneity in cancer and re-analyse the extent of genetic heterogeneity within seven types of untreated epithelial cancers, with particular regard to its clinical relevance. We find that the homogeneity of predicted functional mutations in driver genes is the rule rather than the exception. In primary tumours with multiple samples, 97% of driver-gene mutations in 38 patients were homogeneous. Moreover, among metastases from the same primary tumour, 100% of the driver mutations in 17 patients were homogeneous. With a single biopsy of a primary tumour in 14 patients, the likelihood of missing a functional driver-gene mutation that was present in all metastases was 2.6%. Furthermore, all functional driver-gene mutations detected in these 14 primary tumours were present among all their metastases. Finally, we found that individual metastatic lesions responded concordantly to targeted therapies in 91% of 44 patients. These analyses indicate that the cells within the primary tumours that gave rise to metastases are genetically homogeneous with respect to functional driver-gene mutations, and we suggest that future efforts to develop combination therapies have the potential to be curative.

Entities:  

Mesh:

Year:  2019        PMID: 31455892      PMCID: PMC6816333          DOI: 10.1038/s41568-019-0185-x

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  127 in total

Review 1.  Somatic mutation in cancer and normal cells.

Authors:  Iñigo Martincorena; Peter J Campbell
Journal:  Science       Date:  2015-09-24       Impact factor: 47.728

2.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Authors:  Keith T Flaherty; Jeffery R Infante; Adil Daud; Rene Gonzalez; Richard F Kefford; Jeffrey Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Nageatte Ibrahim; Ragini Kudchadkar; Howard A Burris; Gerald Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Igor Puzanov; Peter Lebowitz; Ajay Singh; Shonda Little; Peng Sun; Alicia Allred; Daniele Ouellet; Kevin B Kim; Kiran Patel; Jeffrey Weber
Journal:  N Engl J Med       Date:  2012-09-29       Impact factor: 91.245

Review 3.  Tumor heterogeneity.

Authors:  G H Heppner
Journal:  Cancer Res       Date:  1984-06       Impact factor: 12.701

Review 4.  Cancer genome landscapes.

Authors:  Bert Vogelstein; Nickolas Papadopoulos; Victor E Velculescu; Shibin Zhou; Luis A Diaz; Kenneth W Kinzler
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

5.  Comparative lesion sequencing provides insights into tumor evolution.

Authors:  Siân Jones; Wei-Dong Chen; Giovanni Parmigiani; Frank Diehl; Niko Beerenwinkel; Tibor Antal; Arne Traulsen; Martin A Nowak; Christopher Siegel; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Joseph Willis; Sanford D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-12       Impact factor: 11.205

6.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Authors:  Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

7.  Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.

Authors:  Nicholas McGranahan; Francesco Favero; Elza C de Bruin; Nicolai Juul Birkbak; Zoltan Szallasi; Charles Swanton
Journal:  Sci Transl Med       Date:  2015-04-15       Impact factor: 17.956

8.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.

Authors:  Luis A Diaz; Richard T Williams; Jian Wu; Isaac Kinde; J Randolph Hecht; Jordan Berlin; Benjamin Allen; Ivana Bozic; Johannes G Reiter; Martin A Nowak; Kenneth W Kinzler; Kelly S Oliner; Bert Vogelstein
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

9.  Evolutionary dynamics of cancer in response to targeted combination therapy.

Authors:  Ivana Bozic; Johannes G Reiter; Benjamin Allen; Tibor Antal; Krishnendu Chatterjee; Preya Shah; Yo Sup Moon; Amin Yaqubie; Nicole Kelly; Dung T Le; Evan J Lipson; Paul B Chapman; Luis A Diaz; Bert Vogelstein; Martin A Nowak
Journal:  Elife       Date:  2013-06-25       Impact factor: 8.140

Review 10.  Catch my drift? Making sense of genomic intra-tumour heterogeneity.

Authors:  Andrea Sottoriva; Chris P Barnes; Trevor A Graham
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-01-07       Impact factor: 10.680

View more
  48 in total

Review 1.  Genetic and non-genetic clonal diversity in cancer evolution.

Authors:  James R M Black; Nicholas McGranahan
Journal:  Nat Rev Cancer       Date:  2021-03-16       Impact factor: 60.716

Review 2.  The pancreatic cancer genome revisited.

Authors:  Akimasa Hayashi; Jungeui Hong; Christine A Iacobuzio-Donahue
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-04       Impact factor: 46.802

Review 3.  Genomic and phenotypic heterogeneity in prostate cancer.

Authors:  Michael C Haffner; Wilbert Zwart; Martine P Roudier; Lawrence D True; William G Nelson; Jonathan I Epstein; Angelo M De Marzo; Peter S Nelson; Srinivasan Yegnasubramanian
Journal:  Nat Rev Urol       Date:  2020-12-16       Impact factor: 14.432

Review 4.  Liquid biopsy enters the clinic - implementation issues and future challenges.

Authors:  Michail Ignatiadis; George W Sledge; Stefanie S Jeffrey
Journal:  Nat Rev Clin Oncol       Date:  2021-01-20       Impact factor: 66.675

Review 5.  A compendium of mutational cancer driver genes.

Authors:  Francisco Martínez-Jiménez; Ferran Muiños; Inés Sentís; Jordi Deu-Pons; Iker Reyes-Salazar; Claudia Arnedo-Pac; Loris Mularoni; Oriol Pich; Jose Bonet; Hanna Kranas; Abel Gonzalez-Perez; Nuria Lopez-Bigas
Journal:  Nat Rev Cancer       Date:  2020-08-10       Impact factor: 60.716

Review 6.  A systems biology approach to discovering pathway signaling dysregulation in metastasis.

Authors:  Robert Clarke; Pavel Kraikivski; Brandon C Jones; Catherine M Sevigny; Surojeet Sengupta; Yue Wang
Journal:  Cancer Metastasis Rev       Date:  2020-08-10       Impact factor: 9.264

Review 7.  Targeting metastatic cancer.

Authors:  Karuna Ganesh; Joan Massagué
Journal:  Nat Med       Date:  2021-01-13       Impact factor: 53.440

8.  Genomic Correlates of DNA Damage in Breast Cancer Subtypes.

Authors:  Esther Cabañas Morafraile; Javier Pérez-Peña; Jesús Fuentes-Antrás; Aránzazu Manzano; Pedro Pérez-Segura; Atanasio Pandiella; Eva M Galán-Moya; Alberto Ocaña
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

9.  Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.

Authors:  Jeanne Tie; Joshua D Cohen; Serigne N Lo; Yuxuan Wang; Lu Li; Michael Christie; Margaret Lee; Rachel Wong; Suzanne Kosmider; Iain Skinner; Hui Li Wong; Belinda Lee; Matthew E Burge; Desmond Yip; Christos S Karapetis; Timothy J Price; Niall C Tebbutt; Andrew M Haydon; Janine Ptak; Mary J Schaeffer; Natalie Silliman; Lisa Dobbyn; Maria Popoli; Cristian Tomasetti; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Peter Gibbs
Journal:  Int J Cancer       Date:  2020-10-06       Impact factor: 7.396

10.  MiR-6838-5p facilitates the proliferation and invasion of renal cell carcinoma cells through inhibiting the DMTF1/ARF-p53 axis.

Authors:  Xiaoqiang Zhai; Yan Wu; Dong Zhang; Hecheng Li; Tie Chong; Jun Zhao
Journal:  J Bioenerg Biomembr       Date:  2021-03-08       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.